AmpleLogic Launches Advanced aPaaS for Life Sciences with 14 Ready-to-Use Applications

June 03, 2024 10:30 PM PDT | By Cision

Google News:

AmpleLogic Launches Advanced aPaaS for Life Sciences with 14 Ready-to-Use Applications — Image source: Kalkine Media

Recent News

Paymentus Holdings (NYSE:PAY) A Key Player in Digital Billing within t...

Best Nasdaq Stocks: Why NVIDIA (NASDAQ:NVDA) is a Market Leader in the...

MasterCraft Boat Holdings (NASDAQ:MCFT) Powerboat Manufacturer on the...

Neurocrine Biosciences (NASDAQ:NBIX) A Key Player in the nasdaq index

HYDERABAD, India, June 4, 2024 /PRNewswire/ -- AmpleLogic, a leading provider of GAMP solutions, announces the launch of its revolutionary Application Platform as a Service (aPaaS) designed specifically for the life sciences sector. This cutting-edge platform leverages low-code/no-code technology to accelerate digitization in life sciences industry while enhancing operational efficiency and ensuring compliance with regulatory standards from USFDA, MHRA, EMEA, ISO, and GAMP guidelines.

AmpleLogic's aPaaS platform offers a unique Build Your Own Application (BYOA) feature, enabling companies to quickly respond to emerging regulatory requirements and operational challenges. They can customize an application using the platform specific to their business use case.

Additionally, AmpleLogic also offers a comprehensive suite of 14 ready-to-use, pre-validated applications designed for regulated industries such as pharmaceuticals manufacturing, biotechnology, medical devices, gene therapy, beauty & cosmetics, food & beverages, and more. These include:

Annual Product Quality Review Software
Quality Management System
Manufacturing Execution System
Electronic Logbook System
Environmental Monitoring System
Document Management System
Learning Management System
Cleaning Validation System
Process Validation System
Stability Management System
Regulatory Information Management System
Laboratory Information Management System
User Access Management System
Calibration and PM Software

"We are excited to launch our new aPaaS platform made for the life sciences industry, designed to streamline operations and ensure compliance," said Mr. Manne V. Chowdhary, CEO & MD of AmpleLogic. "Our platform leverages the latest technologies to provide scalable and flexible solutions that meet the unique needs of our clients in the life sciences sector. With over 100 happy clients spanning 14 years of operations in this field, this is one of AmpleLogic's many endeavors and a step forward in our mission to deliver innovative and effective software solutions."

AmpleLogic also integrates AI and ML for enhanced solutions, offering predictive analysis and automated SOP-based questionnaire generation. Their Learning Management System uses these technologies for targeted training, ensuring compliance and workforce readiness.

About AmpleLogic:

AmpleLogic is a premier provider of cutting-edge technology solutions for the life sciences industry. Focused on delivering high-quality, compliant, and user-friendly platforms, AmpleLogic helps organizations streamline operations, ensure regulatory compliance and drive growth. Serving small biotech firms to large pharmaceutical companies, AmpleLogic meets unique industry needs with its innovative solutions.

For more information, visit www.amplelogic.com.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.